Loading...
01/11 08:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several negative financial indicators: a significant revenue drop, increased operating expenses, and a larger net loss. Despite some positive developments like the KOSTAIVE launch and strategic partnerships, the financial health and guidance issues weigh heavily. The Q&A section shows management's reluctance to provide clear guidance, adding uncertainty. These factors, along with a lack of strong positive catalysts, suggest a negative sentiment. Without market cap data, we assume a moderate negative reaction in stock price, likely between -2% and -8%.
Revenue (Q4 2024) $22.8 million, a decrease of $8.1 million (26.2%) from $30.9 million in Q4 2023 due to lower milestone achievements from the CSL agreement.
Revenue (Fiscal Year 2024) $152.3 million, a decrease of $14.5 million (8.7%) from $166.8 million in FY 2023, attributed to lower milestone achievements from the CSL agreement, offset by increased BARDA revenue.
Total Operating Expenses (Q4 2024) $56.2 million, an increase of $7.1 million (14.4%) from $49.1 million in Q4 2023, primarily due to higher clinical trial costs.
Total Operating Expenses (Fiscal Year 2024) $248 million, an increase of $3 million (1.2%) from $245 million in FY 2023.
Research and Development Expenses (Q4 2024) $43.8 million, an increase of $7.2 million (19.7%) from $36.6 million in Q4 2023, driven by higher clinical trial costs.
Research and Development Expenses (Fiscal Year 2024) $195.2 million, an increase of $3.1 million (1.6%) from $192.1 million in FY 2023, primarily due to higher clinical trial costs.
General and Administrative Expenses (Q4 2024) $12.4 million, a slight decrease of $0.1 million (0.8%) from $12.5 million in Q4 2023, remaining relatively consistent.
General and Administrative Expenses (Fiscal Year 2024) $52.8 million, a slight decrease of $0.1 million (0.2%) from $52.9 million in FY 2023, remaining relatively consistent.
Net Loss (Q4 2024) $30 million, compared to a net loss of $11.7 million in Q4 2023, reflecting a larger loss of $1.11 per diluted share.
Net Loss (Fiscal Year 2024) $80.9 million, compared to a net loss of $29.7 million in FY 2023, reflecting a larger loss of $3 per diluted share.
Cash and Cash Equivalents (End of Q4 2024) $293.9 million, down from $348.9 million at the end of Q4 2023.
Cash Burn (Fiscal Year 2024) $55 million, compared to $45 million in FY 2023.
KOSTAIVE Vaccine Approval: Received European Commission approval for KOSTAIVE, the world’s first approved self-amplifying mRNA COVID-19 vaccine.
KOSTAIVE U.S. BLA Filing: Anticipated filing for KOSTAIVE in the U.S. later in 2025.
2-Dose Vial Presentation: Meiji Seika Pharma submitted a manufacturing application for a new 2-dose vial presentation of KOSTAIVE in Japan.
ARCT-2304 Phase I Study: Initiated a Phase I study of ARCT-2304, a self-amplifying mRNA vaccine candidate for H5N1.
ARCT-032 Phase II Study: Dosed first participant in a Phase II study for cystic fibrosis.
ARCT-810 Phase II Study: Initiated dosing of the first participant in a Phase II study for ornithine transcarbamylase deficiency.
KOSTAIVE Sales: Reported approximately $28 million in gross profit from KOSTAIVE sales for the quarter ended December 31, 2024.
Investment from Meiji Seika Pharma: Received a $20 million investment from Meiji Seika Pharma.
Manufacturing Approval in Japan: Approval for domestic commercial manufacturing sites in Japan for KOSTAIVE.
Clinical Trial Costs: Increased R&D expenses driven by higher clinical trial costs for CF and OTC programs.
Appointment of Dr. Moncef Slaoui: Announced the appointment of Dr. Moncef Slaoui as Chair designate.
Transition to Commercial Company: Transitioning to a commercial company with the launch of KOSTAIVE.
Earnings Miss: Arcturus Therapeutics reported an EPS of $-1.11, missing expectations of $-0.33, indicating potential financial instability.
Regulatory Approval Risks: While the company received European Commission approval for KOSTAIVE, the U.S. BLA filing is anticipated for later in 2025, which carries risks of delays or rejections.
Revenue Decline: The company reported a revenue decrease of $14.5 million year-over-year, attributed to lower milestone achievements from the CSL agreement, indicating reliance on external partnerships.
Increased Operating Expenses: Total operating expenses increased to $248 million, with R&D expenses rising due to higher clinical trial costs, which may strain financial resources.
Net Loss: Arcturus reported a net loss of approximately $80.9 million for the year, a significant increase from the previous year, raising concerns about sustainability.
Cash Burn Rate: The company anticipates an increase in cash burn over the next two years due to ongoing clinical trials, which could impact liquidity.
Future Milestone Payments: As the COVID program transitions to a commercial phase, development milestones with CSL are expected to decline, potentially affecting future revenue.
Market Competition: The competitive landscape for mRNA vaccines and therapeutics is intense, posing risks to market share and pricing power.
KOSTAIVE Approval: Received European Commission approval for KOSTAIVE, the first self-amplifying mRNA COVID-19 vaccine, valid in all EU member states and 3 additional countries.
U.S. BLA Filing: Anticipated U.S. BLA filing for KOSTAIVE later in 2025.
Manufacturing Expansion: Meiji Seika Pharma submitted a manufacturing application for a new 2-dose vial presentation of KOSTAIVE in Japan, aiming for approval by autumn 2025.
ARCT-2304 Phase I Study: Initiated a Phase I study of ARCT-2304 for pandemic influenza, with interim data expected in the second half of 2025.
ARCT-032 Phase II Study: Dosed first participant in Phase II study for cystic fibrosis, with interim data expected by end of Q2 2025.
ARCT-810 Phase II Study: Initiated dosing in Phase II study for OTC deficiency, with interim data expected by end of Q2 2025.
Leadership Appointment: Appointment of Dr. Moncef Slaoui as Chair designate, enhancing leadership in biotech.
Revenue Expectations: Reported revenues of $152.3 million for FY 2024, a decrease from $166.8 million in FY 2023.
Net Loss: Net loss of approximately $80.9 million for FY 2024, compared to $29.7 million in FY 2023.
Cash Runway: Cash runway expected to extend until the end of Q1 2027.
Future Milestones: Expect to continue receiving milestone payments from CSL supporting ongoing vaccine development.
Operating Expenses: Total operating expenses for FY 2024 were $248 million, slightly up from $245 million in FY 2023.
Burn Rate: Anticipate an increase in burn rate over the next 2 years due to CF and OTC program advancements.
Share of gross profit from KOSTAIVE sales: Approximately $28 million for the quarter ended December 31, 2024.
Future profit sharing from CSL: Arcturus will begin to receive shared net profit payments from CSL for all future sales of KOSTAIVE after CSL recoups 40% of total development costs.
Investment by Meiji Seika Pharma: $20 million investment in ARCALIS.
Total upfront payments and milestones from CSL: Approximately $473.1 million as of December 31, 2024.
The earnings call summary and Q&A reveal mixed signals. While there are positive developments in product pipelines and regulatory progress, management's lack of specific guidance on revenue and clinical endpoints creates uncertainty. The Q&A highlighted potential for growth but also pointed to uncertainties in clinical trial outcomes and commercial revenues. No major catalysts like new partnerships or strong financial metrics were announced, leading to a neutral sentiment overall.
The earnings call presents a mixed picture: strong pipeline developments with FDA fast track designation and cash runway extension are positives, but declining revenue and a net loss are negatives. The Q&A reveals cautious optimism about CF and OTC programs, yet management's lack of clarity on competitor impact and data release timing raises uncertainties. These factors, combined with no new partnerships or shareholder return changes, suggest a neutral stock movement prediction.
The earnings call reveals a decline in revenue and increased net loss, alongside an extended cash runway due to cost reductions and facility consolidation. The Q&A session highlights uncertainties, with management avoiding clear answers on key milestones and guidance. Despite a decrease in expenses, the lack of anticipated revenue milestones until 2028 and unclear regulatory feedback contribute to a negative sentiment. While some operational efficiencies were achieved, the overall financial outlook and management's vague responses suggest a negative stock price movement in the short term.
The earnings call reveals several negative financial indicators: a significant revenue drop, increased operating expenses, and a larger net loss. Despite some positive developments like the KOSTAIVE launch and strategic partnerships, the financial health and guidance issues weigh heavily. The Q&A section shows management's reluctance to provide clear guidance, adding uncertainty. These factors, along with a lack of strong positive catalysts, suggest a negative sentiment. Without market cap data, we assume a moderate negative reaction in stock price, likely between -2% and -8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
